Comparison of Clinical Characteristic and Prognosis between Ovarian Clear Cell Carcinoma and Serous Carcinoma: A 10-Year Cohort Study of Chinese Patients

被引:12
|
作者
Ye, Shuang [1 ,2 ]
Yang, Jiaxin [1 ,2 ]
You, Yan [2 ,3 ]
Cao, Dongyan [1 ,2 ]
Huang, Huifang [1 ,2 ]
Wu, Ming [1 ,2 ]
Chen, Jie [2 ,3 ]
Lang, Jinghe [1 ,2 ]
Shen, Keng [1 ,2 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, Beijing 100730, Peoples R China
来源
PLOS ONE | 2015年 / 10卷 / 07期
基金
中国国家自然科学基金;
关键词
HISTOLOGICAL SUBTYPES; TUMOR TYPE; STAGE-I; CANCER; CHEMOTHERAPY; CA-125; ADENOCARCINOMA;
D O I
10.1371/journal.pone.0133498
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives To compare the clinicopathologic features and prognosis of Chinese patients with ovarian clear cell carcinoma (CCC) and serous carcinoma (SC). Methods A retrospective cohort study was designed to investigate the clinicopathologic characteristic and prognosis of patients with CCC and SC who were diagnosed and treated in in a tertiary referral center (Peking Union Medical College Hospital) between 1999 and 2009. The Kaplan-Meier method and Cox regression were employed in the survival analysis. Results A total of 504 cases were included in the study, comprising 197 cases of CCC and 307 cases of SC. The mean age of the patients with SC was greater than of CCC patients (3.6 +/- 0.94, P<0.001). Patients with CCC were more likely to be early-stage and optimally debulked (P<0.001). Regarding cancer-antigen 125, 22% of the patients with CCC had normal values, and the level was significantly lower than in patients with SC (P<0.001). More CCC patients had platinum-resistant tumors compared with platinum-sensitive disease (45.7% in CCC vs. 61.0% in SC [P=0.008]). The 5-year survival rate was 51.2% in the CCC group vs. 49.8% in the SC group (P=0.428). Patients with advanced CCC had a statistically significant poorer overall survival (OS) compared with their SC counterparts (38.0 vs. 52.0 months; hazard ratio 1.584, 95% confidence interval [CI] 1.167-2.150, P=0.003). However, the advantage of improved progression-free survival (PFS) existed across all stages. Conclusions Women with ovarian CCC presented at a younger age and early stage. Patients with ovarian CCC also had improved PFS, but they had similar OS compared to patients with SC. However, patients with advanced CCC had decreased survival.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] SEROUS SURFACE PAPILLARY CARCINOMA - A CLINICOPATHOLOGIC STUDY OF 10 CASES AND COMPARISON WITH STAGE-III-STAGE-IV OVARIAN SEROUS CARCINOMA
    MILLS, SE
    ANDERSEN, WA
    FECHNER, RE
    AUSTIN, MB
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1988, 12 (11) : 827 - 834
  • [42] Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis
    Hee Seung Kim
    Min A. Kim
    Maria Lee
    Dong Hoon Suh
    Kidong Kim
    Jae Hong No
    Hyun Hoon Chung
    Yong Beom Kim
    Yong Sang Song
    [J]. Annals of Surgical Oncology, 2015, 22 : 2738 - 2745
  • [43] Effect of Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma: A Two-Center Cohort Study and Meta-analysis
    Kim, Hee Seung
    Kim, Min A.
    Lee, Maria
    Suh, Dong Hoon
    Kim, Kidong
    No, Jae Hong
    Chung, Hyun Hoon
    Kim, Yong Beom
    Song, Yong Sang
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (08) : 2738 - 2745
  • [44] CLINICAL CHARACTERISTICS AND PROGNOSIS OF ANTIPHOSPHOLIPID SYNDROME PATIENTS BASED ON CLUSTER ANALYSIS: A 10-YEAR COHORT STUDY
    Qi, W.
    Zhao, J. L.
    Tian, X.
    Li, M.
    Zeng, X.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 178 - 178
  • [45] Is there a survival difference between clear cell and serous carcinoma of the endometrium? A stage and age-matched cohort study.
    Slomovitz, BM
    Coleman, RL
    Soliman, PT
    Ramondetta, LM
    Wolf, J
    Sun, CC
    Gershenson, DM
    Burke, TW
    Lu, KH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 474S - 474S
  • [46] Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma
    Huang, Huei-Jean
    Yang, Lan-Yan
    Tung, Hsiu-Jung
    Ku, Fei-Chun
    Wu, Ren-Chin
    Tang, Yun-Hsin
    Chang, Wei-Yang
    Jung, Shih-Ming
    Wang, Chun-Chieh
    Lin, Cheng-Tao
    Liu, Feng-Yuan
    Lin, Gigin
    Chen, Min-Yu
    Chou, Hung-Hsueh
    Chang, Ting-Chang
    Chao, Angel
    Lai, Chyong-Huey
    [J]. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (04) : 793 - 804
  • [47] Immunoediting, neoantigen frequency, and clinical outcome in patients with ovarian clear cell carcinoma
    Hasegawa, K.
    Matsushita, H.
    Oda, K.
    Yamamoto, S.
    Nishijima, A.
    Imai, Y.
    Asada, K.
    Ikeda, Y.
    Fujiwara, K.
    Aburatani, H.
    Kakimi, K.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 145 : 7 - 8
  • [48] The Association Between Race and 5-year Survival in Patients With Clear Cell Renal Cell Carcinoma: A Cohort Study EDITORIAL COMMENT
    Russo, Paul
    [J]. UROLOGY, 2021, 148 : 190 - 190
  • [49] Comparison of long-term outcomes between Chinese peritoneal dialysis patients with and without diabetes: A 10-year cohort study
    Zhang, Difei
    Yang, Yang
    Li, Rongrong
    Li, Zewen
    Wu, Jianfeng
    Liu, Hui
    Xu, Yuan
    Hou, Haijing
    Peng, Yu
    Liu, Xusheng
    Lu, Fuhua
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2021, 35 (05)
  • [50] Correlation between the expression of glutathione metabolism related genes and prognosis in ovarian clear cell carcinoma
    Asano, Hiroshi
    Matsuoka, Ryosuke
    Hatanaka, Kanako C.
    Hatanaka, Yutaka
    Kato, Tatsuya
    Konno, Yosuke
    Mitamura, Takashi
    Akita, Hirotoshi
    Matsuno, Yoshihiro
    Watari, Hidemichi
    [J]. CANCER RESEARCH, 2019, 79 (13)